In recognition of Pancreatic Cancer Awareness Month, cutting-edge technologies are transforming our understanding of pancreatic ductal adenocarcinoma (PDAC).
Presented by Dr. Max Reichert, this topic explores pancreatic ductal adenocarcinoma (PDAC) and its extensive cellular heterogeneity, underlying its aggressive clinical behavior and resistance to therapy.
PDAC exhibits extensive cellular heterogeneity, which underlies its aggressive clinical behavior and resistance to therapy.
Author's summary: Cutting-edge tech transforms PDAC understanding.